RxDoctor Payments Data

Jonathan Williams

Gastroenterology · Kenilworth, ILNPI 1013195650

Payments from drug & device makers

$16,210in general payments, 2019–2025

Across 43 payments — averaging $376.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$15K
  • Braintree Laboratories, Inc.$635
  • Johnson & Johnson$160
  • Celltrion USA Inc.$124
  • AbbVie$72
  • Romark Laboratories, LC$63
  • plus $101 from 4 others
$689in research payments, 2019–2025

Across 1 payment — averaging $689.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$689

What the payments were for

  • Food & beverage$52045%
  • Education$71%
  • Gifts$62854%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly4$15,054
Braintree Laboratories, Inc.14$635
Johnson & Johnson9$160
Celltrion USA Inc.1$124
AbbVie(2 entities)5$72
Romark Laboratories, LC4$63
Ironwood Pharmaceuticals, Inc3$47
Gilead1$19
QOL Medical, LLC1$18
Concordia Pharmaceuticals Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,210 in reported general payments places this provider in the 80th percentile of 787 gastroenterology providers in Illinois.

See all gastroenterology providers in Illinois

Medicare billing

Part B allowed, 2024
$345,237
Medicare patients
980
Services billed
3,807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase34$69,668
LinzessLinaclotide39$30,623
Mesalamine47$19,142
Dexlansoprazole DrDexlansoprazole19$8,540
Budesonide EcBudesonide16$6,703
Omeprazole503$6,001
Budesonide DrBudesonide44$4,233
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag32$3,979
Mesalamine ErMesalamine14$2,069
CholestyramineCholestyramine (With Sugar)30$1,986
Pantoprazole Sodium134$1,673
Rabeprazole Sodium11$1,025
Famotidine73$775
Dicyclomine Hcl28$679
Sulfasalazine19$601

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$72$100,29173 claims
Braintree Laboratories, Inc.Suflave$635$3,97932 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 787 gastroenterology providers in Illinois.

Other gastroenterology in Kenilworth

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →